Search Protocols under revision. Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupGastroenterologic OncologySarcomasSarcomas (ped.)DiseaseLiver Sarcoma UndifferentiatedRhabdomyosarcomaSoft Tissue SarcomaSubgroupICD10C49.-MeSHHemangiosarcomaRhabdomyosarcoma, EmbryonalSequencePAED Soft Tissue Sarcoma, "Non-RMS-like"-tumors (NRSTS) in the High Risk GroupPAED Soft Tissue Sarcoma, CWS-PROPOSAL FOR ANGIOSARCOMAPAED Soft Tissue Sarcoma, Localised "RMS-like" tumours (SySa, STET (EES, pPNET), UDS)PAED Soft Tissue Sarcoma, Primary metastatic soft tissue tumoursPAED Soft Tissue Sarcoma, RMS Low Risk Group - Subgroup APAED Soft Tissue Sarcoma, RMS Standard Risk Group - Subgroup BPAED Soft Tissue Sarcoma, RMS Very High Risk Group- Subgroup HPAED Soft Tissue Sarcoma, second line therapy according to CWS-2002-P (TECC)PAED Soft Tissue Sarcoma, second line therapy ACCTTIVEPAED Soft Tissue Sarcoma, second line therapy CWS-91-REZPAED Weichteilsarkom, RMS Standard Risk Group – Subgroup CPAED Weichteilsarkom, RMS Standard Risk Group – Subgroup D, E, F, GVAIA III, Soft Tissue SarcomaChemotherapyChemo-substanceCarboplatinCyclophosphamideDactinomycinDoxorubicinEpirubicinEtoposideIdarubicinIfosfamidePaclitaxelTopotecanTrofosfamideVincristineChemo-substanceCarboplatinCyclophosphamideDactinomycinDoxorubicinEpirubicinEtoposideIdarubicinIfosfamidePaclitaxelTopotecanTrofosfamideVincristineChemo-substanceCarboplatinCyclophosphamideDactinomycinDoxorubicinEpirubicinEtoposideIdarubicinIfosfamidePaclitaxelTopotecanTrofosfamideVincristineChemo-substanceCarboplatinCyclophosphamideDactinomycinDoxorubicinEpirubicinEtoposideIdarubicinIfosfamidePaclitaxelTopotecanTrofosfamideVincristineNo. Substances123 RadiotherapySupportive therapySupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMesnaPegfilgrastimSupportive substanceAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMesnaPegfilgrastimNo. Substances12458Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseTherapy intentioncurativepalliativeRisksEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaNeutropeniaOral Mucositis only studiesPublicationAuthorKoscielniak E, Klingebiel TTreuner J. Koscielniak EDiseaseWeichteilsarkom, HRWeichteilsarkom, Kinder, Jugendliche und junge ErwachseneOriginCWS 2002 Protokoll der Gesellschaft für pädiatrische Onkologie und Hämatologie (GPOH)Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH), Studienprotokoll CWS-GuidanceProtocols in Revision 25 protocols foundPAED CWS-Guidance, ACCTTIVE - Vincristine 1.5 / Doxorubicin 20 / Cyclophosphamide 1200, Soft Tissue Sarcoma (PID1311 V1.0)PAED CWS-Guidance, CEVAIE, CEV - Carboplatin 500 / Epirubicin 150 / Vincristine 1.5, Vincristine intensification, Soft Tissue Sarcoma (PID1296 V1.0)PAED CWS-Guidance, CEVAIE, CEV - Carboplatin 500 / Epirubicin 150 / Vincristine 1.5, Soft Tissue Sarcoma (PID1297 V1.0)PAED CWS-Guidance, CEVAIE, I³VA- Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Vincristine intensification, Soft Tissue Sarcoma (PID1293 V1.0)PAED CWS-Guidance, CEVAIE, I³VA- Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Soft Tissue Sarcoma (PID1294 V1.0)PAED CWS-Guidance, CEVAIE, I³VE - Ifosfamide 3 / Vincristine 1.5 / Etoposide 150, Soft Tissue Sarcoma (PID1298 V1.0)PAED CWS-Guidance, CWS-91-REZ, Block A - Carboplatin 150 / Etoposide 150, Soft Tissue Sarcoma (PID1305 V1.1)PAED CWS-Guidance, CWS-91-REZ, Block B- Ifosfamide 2 / Etoposide 150, Soft Tissue Sarcoma (PID1306 V1.0)PAED CWS-Guidance, CWS-91-REZ, Block C - Carboplatin 150 / Ifosfamide 2, Soft Tissue Sarcoma (PID1307 V1.0)PAED CWS-Guidance, I²VA - Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, VNCR intensification, Soft Tissue Sarcoma (PID1287 V1.0)PAED CWS-Guidance, I²VA - Ifosfamide 3 / Vincristine 1.5 / Dactinomycin 1.5, Soft Tissue Sarcoma (PID1288 V1.0)PAED CWS-Guidance, I²VAd - Ifosfamide 3 / Vincristine 1.5 / Doxorubicin 20, Vincristine intensification, Soft Tissue Sarcoma (PID1290 V1.0)PAED CWS-Guidance, I²VAd - Ifosfamide 3 / Vincristine 1.5 / Doxorubicin 20, Soft Tissue Sarcoma (PID1292 V1.0)PAED CWS-Guidance, O-TE - Trofosfamide 75 / Etoposide 25, Soft Tissue Sarcoma, maintenance (PID1304 V1.0)PAED CWS-Guidance, O-TI - Trofosfamide 75 / Idarubicin 5, Soft Tissue Sarcoma, Maintenance (PID1303 V1.0)PAED CWS-Guidance, Paclitaxel 200, Angiosarcoma (PID1320 V1.0)PAED CWS-Guidance, TECC Block A / ACCTTIVE - Topotecan 1 / Carboplatin 150, Soft Tissue Sarcoma (PID1308 V1.0)PAED CWS-Guidance, TECC Block B - Topotecan 1 / Cyclophosphamide 250, Soft Tissue Sarcoma (PID1309 V1.0)PAED CWS-Guidance, TECC Block C / ACCTTIVE - Carboplatin 150 / Etoposide 150, Soft Tissue Sarcoma (PID1310 V1.0)PAED CWS-Guidance, VA - Vincristine 1.5 / Dactinomycin 1.5, Rhabdomyosarcoma (PID1237 V1.0)PAED CWS-Guidance, VA2 - Vincristine 1.5 / Dactinomycin 1.5, Rhabdomyosarcoma (PID1289 V1.0)VAIA III Block 1 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID657 V1.2)VAIA III Block 2 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID659 V1.3)VAIA III Block 3,4,6 - Vincristine 1.5 / Ifosfamide 3 / Doxorubicin 40, Soft Tissue Sarcoma (PID660 V1.2)VAIA III Block 5,7,8,9 - Vincristine 1.5 / Dactinomycin 1.5 / Ifosfamide 3, Soft Tissue Sarcoma (PID661 V1.3)
